17:02 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, CRISPR interference (CRISPRi)-based method of mapping genetic interactions could help identify new drug targets for cancer and genetic disorders. The method involves: selecting sgRNAs against genes identified...
18:16 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuing Phase III of Axsome's AXS-02 for complex regional pain syndrome

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended discontinuing for futility the Phase III CREATE-1 trial of once-weekly oral AXS-02 (disodium zoledronate tetrahydrate) for six weeks to treat pain associated with complex regional pain syndrome...
18:02 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

IDMC recommends continuation of Phase III knee OA trial for Axsome's AXS-02

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended continuing the Phase III COAST-1 trial of AXS-02 (disodium zoledronate tetrahydrate) to treat pain caused by osteoarthritis (OA) of the knee associated with bone marrow lesions following...
07:00 , Sep 2, 2010 |  BC Innovations  |  Targets & Mechanisms

Going to bis-school

A team at Novartis AG has identified the first non-bisphosphonate inhibitors of farnesyl diphosphate synthase,1 an enzyme targeted by bone-specific bisphosphonates that are approved to treat benign and malignant bone diseases. The researchers believe the...
07:00 , Sep 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Farnesyl diphosphate synthase (FDPS; FPPS) In vitro studies identified non-bisphosphonate FPPS inhibitors that may help treat...